Expanded Access Program for Avapritinib
NCT04714086 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-10-24
Summary
This record comprises the currently available Expanded Access Programs (EAP) for avapritinib (BLU-285):
1\) A Post Trial Access (PTA) program to provide continued access to treatment with avapritinib to BLU-285-1107 participants with solid tumors who are unable to access commercially available avapritinib after trial BLU-285-1107 (NCT04908176) has ended.
Conditions
Interventions
- DRUG
-
Avapritinib
Avapritinib will be administered orally at 300 mg QD.
Sponsors & Collaborators
-
Blueprint Medicines Corporation
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
NCT02365662 ·Status: TERMINATED ·Phase: PHASE1
-
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
NCT02589717 ·Status: APPROVED_FOR_MARKETING
-
A Study of ABT-414 in Subjects With Solid Tumors
NCT01741727 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03071757 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
NCT00661609 ·Status: COMPLETED ·Phase: PHASE2
-
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
NCT04777994 ·Status: RECRUITING ·Phase: PHASE1
-
An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
NCT01406119 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
NCT07241039 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of ABT-165 in Subjects With Solid Tumors
NCT01946074 ·Status: COMPLETED ·Phase: PHASE1
-
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
NCT01110486 ·Status: COMPLETED ·Phase: PHASE1
-
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
NCT05480865 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
NCT01316822 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
NCT03125200 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
NCT03145909 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
NCT02391480 ·Status: COMPLETED ·Phase: PHASE1
-
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
NCT00463814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of ARRY-334543 in Patients With Advanced Cancer
NCT00278902 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03821935 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
NCT04272203 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
NCT04736394 ·Status: RECRUITING ·Phase: PHASE3
-
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
NCT04383938 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of APR-1051 in Patients With Advanced Solid Tumors
NCT06260514 ·Status: RECRUITING ·Phase: PHASE1